Navigation Links
Pepscan Achieves First Milestone in Research Collaboration With Genmab
Date:3/10/2009

LELYSTAD, The Netherlands, March 10 /PRNewswire/ -- Pepscan Therapeutics (Pepscan) today announced that it has earned a milestone payment from Genmab A/S. The milestone payment arises from an ongoing Research Collaboration aimed at identifying human antibodies against intractable targets. Pepscan is responsible for using it CLIPS(TM) technology to generate immunogens that mimic the protein targets to induce human antibodies against these intractable targets.

Under the terms of the collaboration agreement, Pepscan is eligible to receive additional payments from Genmab upon the achievement of certain development and regulatory milestones. Pepscan is also eligible to receive royalties on potential sales of any therapeutics developed as a result of the collaboration.

"The achievement of this milestone further validates Pepscan's CLIPS(TM) platform", said Rob Meloen, CSO of Pepscan Therapeutics. "We are pleased to see the significant progress that has been made in the collaboration with Genmab."

About Intractable Targets

"Intractable" Targets are drug targets that would be desirable to address with monoclonal antibodies but are inaccessible with alternative commercially available technologies. This can be due to the fact that target proteins are buried to a large extent very close to the cell surface or in the cell membrane or due to poor immunogenicity of the protein or desirable epitopes.

About Pepscan Therapeutics

Pepscan Therapeutics is a product focused immunotherapy company based in the Netherlands. It has developed a pipeline of therapeutic vaccine and antibody programs of which the most advanced is in Phase II clinical testing. Pepscan's proprietary and innovative CLIPS(TM) technology has proven to yield functional antibodies reactive with a range of complex proteins, including GPCRs.

About CLIPS(TM) Technology

Chemically Linked Immunogenic Peptides on Scaffolds (CLIPS(TM)) is a technology to present one or more peptides in a structurally constrained configuration. These molecules behave as functional mimics of complex protein domains that serve as superior immunogens in the induction and selection of antibodies against disease relevant protein targets. This is especially valuable in the case of proteins that are inaccessible as recombinant proteins (e.g. GPCRs, ion channels, patented proteins).


'/>"/>
SOURCE Pepscan Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Genmab and Pepscan to Identify Human Antibodies Against Intractable Targets
2. Pharsight Achieves First License Sale for Public-Source Database
3. GenoLogics Geneus Achieves GeneChip-compatible(TM) Status with the Affymetrix GeneChip(R) Microarray Platform
4. Sanofi Pasteurs Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
5. Signalife Achieves $1.98 Million Sales Orders Thus Far
6. Diplomat Specialty Pharmacy Health Services Division Achieves High Marks in Pilot Program for Chronic Kidney Disease Management
7. Dalton Medicinal Chemistry Partners Achieves Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
8. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
9. Sigma-Aldrich Achieves Double Accreditation as a Certified Reference Material Producer Following ISO/IEC 17025 and ISO Guide 34
10. NOLabs AB Achieves Break-Through in Fight Against MRSA-Bacteria
11. BIAS Achieves Certified Advantage Partner Level in Oracle PartnerNetwork
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... ... January 13, 2017 , ... ... demand that it has found among its diverse customer base. The latest entry ... in most brands electroporators including BTX and Bio-Rad. FireflySci is introducing three distinct ...
(Date:1/12/2017)... ... January 12, 2017 , ... ... of performing routine electrochemical biosensing has increased dramatically. Primarily driven by the ... and quantification of various analytes in complex samples. , Screen-printed ...
(Date:1/12/2017)... 2017   Protein Sciences Corporation , a ... Flublok Influenza Vaccine ®, announced today that its ... safety results and induced strong neutralizing antibodies against ... is expected to advance into human clinical trials ... Institute of Technology in Immunobiologicals of the Oswaldo ...
(Date:1/11/2017)... ... January 11, 2017 , ... Phase 1 clinical trial ... of the investigational anti-cancer agent tucatinib (formerly ONT-380) against HER2+ breast cancer. The ... percent of these heavily pretreated patients saw clinical benefit from the drug, with ...
Breaking Biology Technology:
(Date:12/15/2016)... Germany , December 15, 2016 ... today announced an agreement with NuData Security, an award-winning ... The partnership will enable clients to focus on good customer ... data protection regulation. ... In order to provide a one-stop fraud prevention ...
(Date:12/15/2016)... 2016 Advancements in biometrics will ... and wellbeing (HWW), and security of vehicles ... passenger vehicles begin to feature fingerprint recognition, ... beat monitoring, brain wave monitoring, stress detection, ... pulse detection. These will be driven by ...
(Date:12/12/2016)...  Researchers at Trinity College, Dublin, are opening ... the material with Silly Putty. The mixture (known as ... to sense pulse, blood pressure, respiration, and even ... The research team,s findings were published Thursday ... http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):